CN113995142B - 一种含有植物螯合肽的组合物及其制备方法 - Google Patents
一种含有植物螯合肽的组合物及其制备方法 Download PDFInfo
- Publication number
- CN113995142B CN113995142B CN202111314565.3A CN202111314565A CN113995142B CN 113995142 B CN113995142 B CN 113995142B CN 202111314565 A CN202111314565 A CN 202111314565A CN 113995142 B CN113995142 B CN 113995142B
- Authority
- CN
- China
- Prior art keywords
- parts
- phytochelatin
- compound
- amino acid
- coating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108010076986 Phytochelatins Proteins 0.000 title claims abstract description 68
- 239000000203 mixture Substances 0.000 title claims abstract description 60
- 238000002360 preparation method Methods 0.000 title claims abstract description 28
- 239000000284 extract Substances 0.000 claims abstract description 40
- 239000006041 probiotic Substances 0.000 claims abstract description 33
- 235000018291 probiotics Nutrition 0.000 claims abstract description 33
- 239000000843 powder Substances 0.000 claims abstract description 26
- 230000000529 probiotic effect Effects 0.000 claims abstract description 26
- -1 compound amino acid Chemical class 0.000 claims abstract description 22
- 150000001875 compounds Chemical class 0.000 claims abstract description 13
- 239000000047 product Substances 0.000 claims abstract description 10
- 239000002131 composite material Substances 0.000 claims abstract description 9
- 238000000576 coating method Methods 0.000 claims description 37
- 239000011248 coating agent Substances 0.000 claims description 36
- 238000002156 mixing Methods 0.000 claims description 23
- 229940024606 amino acid Drugs 0.000 claims description 21
- 239000008188 pellet Substances 0.000 claims description 20
- 239000002702 enteric coating Substances 0.000 claims description 17
- 238000009505 enteric coating Methods 0.000 claims description 17
- 239000002245 particle Substances 0.000 claims description 15
- 238000003756 stirring Methods 0.000 claims description 15
- 229930014626 natural product Natural products 0.000 claims description 13
- DQJCDTNMLBYVAY-ZXXIYAEKSA-N (2S,5R,10R,13R)-16-{[(2R,3S,4R,5R)-3-{[(2S,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-(ethylamino)-6-hydroxy-2-(hydroxymethyl)oxan-4-yl]oxy}-5-(4-aminobutyl)-10-carbamoyl-2,13-dimethyl-4,7,12,15-tetraoxo-3,6,11,14-tetraazaheptadecan-1-oic acid Chemical compound NCCCC[C@H](C(=O)N[C@@H](C)C(O)=O)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@@H](C)NC(=O)C(C)O[C@@H]1[C@@H](NCC)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DQJCDTNMLBYVAY-ZXXIYAEKSA-N 0.000 claims description 11
- SMDOOINVMJSDPS-UHFFFAOYSA-N Astragaloside Natural products C1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)OC2C(C(OC3C(C(O)C(O)C(CO)O3)O)C(O)C(CO)O2)O)=C1 SMDOOINVMJSDPS-UHFFFAOYSA-N 0.000 claims description 11
- 102000002068 Glycopeptides Human genes 0.000 claims description 11
- 108010015899 Glycopeptides Proteins 0.000 claims description 11
- QMNWISYXSJWHRY-XWJCTJPOSA-N astragaloside Chemical compound O1[C@H](C(C)(O)C)CC[C@]1(C)[C@@H]1[C@@]2(C)CC[C@]34C[C@]4(CC[C@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)CO4)O)C4(C)C)C4[C@@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)CC3[C@]2(C)C[C@@H]1O QMNWISYXSJWHRY-XWJCTJPOSA-N 0.000 claims description 11
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 11
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 11
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- 239000010410 layer Substances 0.000 claims description 10
- 239000011265 semifinished product Substances 0.000 claims description 10
- LUEWUZLMQUOBSB-FSKGGBMCSA-N (2s,3s,4s,5s,6r)-2-[(2r,3s,4r,5r,6s)-6-[(2r,3s,4r,5s,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5s,6r)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@@H](OC3[C@H](O[C@@H](O)[C@@H](O)[C@H]3O)CO)[C@@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O LUEWUZLMQUOBSB-FSKGGBMCSA-N 0.000 claims description 9
- 244000247812 Amorphophallus rivieri Species 0.000 claims description 9
- 235000001206 Amorphophallus rivieri Nutrition 0.000 claims description 9
- 244000037364 Cinnamomum aromaticum Species 0.000 claims description 9
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 claims description 9
- 229920002581 Glucomannan Polymers 0.000 claims description 9
- 229920002752 Konjac Polymers 0.000 claims description 9
- 229940046240 glucomannan Drugs 0.000 claims description 9
- 239000000252 konjac Substances 0.000 claims description 9
- 235000010485 konjac Nutrition 0.000 claims description 9
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 claims description 8
- 239000000654 additive Substances 0.000 claims description 8
- 230000000996 additive effect Effects 0.000 claims description 8
- 239000006084 composite stabilizer Substances 0.000 claims description 8
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 claims description 8
- 239000001685 glycyrrhizic acid Substances 0.000 claims description 8
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 claims description 8
- 229960004949 glycyrrhizic acid Drugs 0.000 claims description 8
- 235000019410 glycyrrhizin Nutrition 0.000 claims description 8
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims description 8
- 239000000463 material Substances 0.000 claims description 8
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 7
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 7
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 7
- 239000007788 liquid Substances 0.000 claims description 7
- 239000000243 solution Substances 0.000 claims description 7
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 6
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 6
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 6
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 6
- 239000003381 stabilizer Substances 0.000 claims description 6
- 229920000623 Cellulose acetate phthalate Polymers 0.000 claims description 5
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 5
- 240000002605 Lactobacillus helveticus Species 0.000 claims description 5
- 235000013967 Lactobacillus helveticus Nutrition 0.000 claims description 5
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 5
- 239000004472 Lysine Substances 0.000 claims description 5
- 238000000889 atomisation Methods 0.000 claims description 5
- 229940081734 cellulose acetate phthalate Drugs 0.000 claims description 5
- 238000001035 drying Methods 0.000 claims description 5
- 239000012467 final product Substances 0.000 claims description 5
- 238000004108 freeze drying Methods 0.000 claims description 5
- 238000007710 freezing Methods 0.000 claims description 5
- 230000008014 freezing Effects 0.000 claims description 5
- 229940054346 lactobacillus helveticus Drugs 0.000 claims description 5
- 239000011259 mixed solution Substances 0.000 claims description 5
- 239000008055 phosphate buffer solution Substances 0.000 claims description 5
- 229940068918 polyethylene glycol 400 Drugs 0.000 claims description 5
- 238000005507 spraying Methods 0.000 claims description 5
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 4
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 4
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 4
- 240000001046 Lactobacillus acidophilus Species 0.000 claims description 4
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 claims description 4
- 240000006024 Lactobacillus plantarum Species 0.000 claims description 4
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims description 4
- 241000186604 Lactobacillus reuteri Species 0.000 claims description 4
- 241000218588 Lactobacillus rhamnosus Species 0.000 claims description 4
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 4
- 229960000310 isoleucine Drugs 0.000 claims description 4
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 4
- 229940039695 lactobacillus acidophilus Drugs 0.000 claims description 4
- 229940072205 lactobacillus plantarum Drugs 0.000 claims description 4
- 229940001882 lactobacillus reuteri Drugs 0.000 claims description 4
- 229930182817 methionine Natural products 0.000 claims description 4
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 claims description 3
- 241000186012 Bifidobacterium breve Species 0.000 claims description 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 3
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 3
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 3
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 3
- 241000186840 Lactobacillus fermentum Species 0.000 claims description 3
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 3
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 3
- 239000004473 Threonine Substances 0.000 claims description 3
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 3
- 229940009289 bifidobacterium lactis Drugs 0.000 claims description 3
- 229940012969 lactobacillus fermentum Drugs 0.000 claims description 3
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 3
- 239000004474 valine Substances 0.000 claims description 3
- 241001134770 Bifidobacterium animalis Species 0.000 claims description 2
- 229940118852 bifidobacterium animalis Drugs 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 230000000968 intestinal effect Effects 0.000 abstract description 13
- 229910001385 heavy metal Inorganic materials 0.000 abstract description 11
- 230000036039 immunity Effects 0.000 abstract description 11
- 230000000694 effects Effects 0.000 abstract description 10
- 239000000126 substance Substances 0.000 abstract description 10
- 238000010521 absorption reaction Methods 0.000 abstract description 6
- 235000015097 nutrients Nutrition 0.000 abstract description 6
- 235000013305 food Nutrition 0.000 abstract description 4
- 150000001413 amino acids Chemical class 0.000 abstract description 3
- 230000036541 health Effects 0.000 abstract description 3
- 235000016709 nutrition Nutrition 0.000 abstract description 3
- 230000035764 nutrition Effects 0.000 abstract description 3
- 239000013589 supplement Substances 0.000 abstract description 3
- 230000001502 supplementing effect Effects 0.000 abstract description 3
- 239000003053 toxin Substances 0.000 abstract description 3
- 231100000765 toxin Toxicity 0.000 abstract description 3
- 229910052793 cadmium Inorganic materials 0.000 abstract description 2
- BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium atom Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 abstract description 2
- 230000000052 comparative effect Effects 0.000 description 25
- 238000000034 method Methods 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- 230000009182 swimming Effects 0.000 description 9
- 210000001035 gastrointestinal tract Anatomy 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 6
- 241000222355 Trametes versicolor Species 0.000 description 6
- 241000196324 Embryophyta Species 0.000 description 5
- 210000004051 gastric juice Anatomy 0.000 description 5
- 230000028993 immune response Effects 0.000 description 5
- 230000001276 controlling effect Effects 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 4
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 4
- 238000005469 granulation Methods 0.000 description 4
- 230000003179 granulation Effects 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 230000004888 barrier function Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 210000002865 immune cell Anatomy 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- OCKGFTQIICXDQW-ZEQRLZLVSA-N 5-[(1r)-1-hydroxy-2-[4-[(2r)-2-hydroxy-2-(4-methyl-1-oxo-3h-2-benzofuran-5-yl)ethyl]piperazin-1-yl]ethyl]-4-methyl-3h-2-benzofuran-1-one Chemical compound C1=C2C(=O)OCC2=C(C)C([C@@H](O)CN2CCN(CC2)C[C@H](O)C2=CC=C3C(=O)OCC3=C2C)=C1 OCKGFTQIICXDQW-ZEQRLZLVSA-N 0.000 description 2
- 206010027439 Metal poisoning Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000013522 chelant Substances 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000003912 environmental pollution Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 210000004211 gastric acid Anatomy 0.000 description 2
- 229960003180 glutathione Drugs 0.000 description 2
- 108010054010 glutathione gamma-glutamylcysteinyltransferase Proteins 0.000 description 2
- 208000010501 heavy metal poisoning Diseases 0.000 description 2
- 210000004347 intestinal mucosa Anatomy 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 210000000582 semen Anatomy 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- LJRDOKAZOAKLDU-UDXJMMFXSA-N (2s,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-[(2r,3s,4r,5s)-5-[(1r,2r,3s,5r,6s)-3,5-diamino-2-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol;sulfuric ac Chemical compound OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO LJRDOKAZOAKLDU-UDXJMMFXSA-N 0.000 description 1
- BQRXMLXVGQMIBO-UHFFFAOYSA-N 1,1-bis(sulfanyl)ethanol Chemical compound CC(O)(S)S BQRXMLXVGQMIBO-UHFFFAOYSA-N 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 206010065559 Cerebral arteriosclerosis Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- SHWNNYZBHZIQQV-UHFFFAOYSA-J EDTA monocalcium diisodium salt Chemical compound [Na+].[Na+].[Ca+2].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O SHWNNYZBHZIQQV-UHFFFAOYSA-J 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 102000008072 Lymphokines Human genes 0.000 description 1
- 108010074338 Lymphokines Proteins 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 241001052560 Thallis Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 201000001883 cholelithiasis Diseases 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000007797 corrosion Effects 0.000 description 1
- 238000005260 corrosion Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000004665 defense response Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 235000021045 dietary change Nutrition 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000037080 exercise endurance Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 208000001130 gallstones Diseases 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 230000007413 intestinal health Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 201000005851 intracranial arteriosclerosis Diseases 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 230000002182 neurohumoral effect Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 229960001639 penicillamine Drugs 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 235000013406 prebiotics Nutrition 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 239000012629 purifying agent Substances 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/30—Encapsulation of particles, e.g. foodstuff additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/113—Acidophilus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/143—Fermentum
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/147—Helveticus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/169—Plantarum
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/173—Reuteri
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/175—Rhamnosus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/519—Breve
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/531—Lactis
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Botany (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明属于保健品技术领域,具体涉及一种含有植物螯合肽的组合物及其制备方法。本发明提供的含有植物螯合肽的组合物包括如下组分及其重量份数:天然复合提取物280~520份,植物螯合肽10~30份,益生菌粉70~150份,复合氨基酸350~400份。本发明的组合物采用益生菌粉与植物螯合肽,复合天然提取物,复合氨基酸结合,能有效调节人体肠道菌群,促进营养物质的吸收,可以补充人体自身不能生成的氨基酸等营养物质,增强人体免疫力,缓解体力疲劳,同时螯合人体通过食物链吸收的重金属,其是对重金属镉Cd2+有特别的吸收作用,对人体更加安全,有效起到了补充营养和排毒的作用,并且制备工艺简单,易于推广应用。
Description
技术领域
本发明属于保健品技术领域,具体涉及一种含有植物螯合肽的组合物及其制备方法。
背景技术
免疫概念及其功能免疫(Immune)来源于拉丁语,中国明朝的《免疫类方》,也表示为“免除疫疠”。免疫是人体的一种重要的生理功能,通过免疫系统识别和清除外来侵入的任何异物(如病原体,化学物等),以维持机体生理平衡的功能。免疫反应(immuneresponse)指的是机体借助理化屏障及神经体液的调节控制,通过免疫细胞及有关的体液因子(如抗体、淋巴因子等)发挥识别自己、排除异己,以维持机体内外环境统一的功能。主要过程为免疫系统接触和识别异己成分或者变异的自体成分,免疫细胞活化、增殖、分化为效应细胞,最终做出防御反应。免疫反应可分为非特异性免疫反应和特异性免疫反应,而特异性免疫反应又可分为T淋巴细胞介导的细胞免疫应答与B淋巴细胞介导的体液免疫应答。多种人体疾病如感冒、肠炎、关节炎症等均与免疫能力低下相关。因此,增强人体免疫力是儿童、青少年、成年人与老年人多年龄群体及各个社会阶层共同的需求。
肠道微生态系统是人体最大、最复杂的微生态系统,也是人体微生态系统中最主要和最活跃的部分。肠道菌群是肠道防御屏障的重要组成部分,平衡的肠道菌群对人的健康十分重要。但是,由于机体衰老、环境污染、饮食改变、滥用抗生素等原因,往往使人体肠道微生态系统受到破坏,引起肠道菌群失调,严重影响身体的免疫系统机能,造成免疫功能低下,导致菌群易位,诱发内源感染,造成机体病变,从而引发多种疾病,如肝硬化、胆结石、动脉硬化、冠心病、心肌梗塞、脑动脉硬化、脑中风等。
而目前,市面上大部分调节肠道菌群的产品,都只是采用简单的益生菌与益生元的组合搭配,并且产品均为胃溶型,不能够抵抗胃肠道恶劣的环境,导致到达后肠的益生菌活菌数大量下降,对肠道调节及免疫力调节的效果大幅下降。
因此,如何制得一种能够避免胃酸的分解,保证有效成分在小肠部位完全释放,充分吸收,有效调节人体肠道菌体,增强人体免疫力的复合型免疫增强产品,成为亟待解决的技术问题。
发明内容
为了解决现有技术中存在的问题,本发明的目的在于提供一种含有植物螯合肽的组合物及其制备方法。本发明提供的含有植物螯合肽的组合物采用益生菌粉与植物螯合肽,复合天然提取物,复合氨基酸结合,能有效调节人体肠道菌群,促进营养物质的吸收,可以补充人体自身不能生成的氨基酸等营养物质,增强人体免疫力,缓解体力疲劳,同时螯合人体通过食物链吸收的重金属,起到补充营养和排毒的作用。
本发明的技术方案是:
一种含有植物螯合肽的组合物,包括如下组分及其重量份数:
天然复合提取物280~520份,植物螯合肽10~30份,益生菌粉70~150份,复合氨基酸350~400份;
进一步地,所述复合提取物由黄芪苷、云芝糖肽、决明子提取物按重量比7~16:11~13:1~6组成。
更进一步地,所述的含有植物螯合肽的组合物,包括如下组分及其重量份数:天然复合提取物450份,植物螯合肽20份,益生菌粉120份,复合氨基酸380份;
更进一步地,所述复合提取物由黄芪苷、云芝糖肽、决明子提取物按重量比14:12:5组成;
进一步地,所述益生菌粉含有嗜酸乳杆菌、植物乳杆菌、鼠李糖乳杆菌、罗伊氏乳杆菌、瑞士乳杆菌、发酵乳杆菌、动物双歧杆菌、乳双歧杆菌或短双岐杆菌中的两种或两种以上的混合菌种;
进一步地,所述复合氨基酸为赖氨酸、色氨酸、苯丙氨酸、甲硫氨酸、苏氨酸、异亮氨酸、亮氨酸、缬氨酸中的两种或两种以上。
进一步地,所述含有植物螯合肽的组合物还包括营养学上可接受的赋形剂、载体或稀释剂。
另外,本发明还提供了所述的含有植物螯合肽的组合物的制备方法,包括如下步骤:
S1、将植物螯合肽,天然复合提取物,益生菌粉,复合氨基酸混合,然后加入其重量1~1.5倍的复合稳定剂,在搅拌转速80~160r/min下搅拌10~30min,混合均匀后投入制粒机内,调节粒度为16~30目,冷冻干燥,得到微丸半成品;
S2、将步骤S1所得的微丸半成品投入至旋流流化床制粒包衣机中进行包膜处理,启动包衣装置,将肠溶包衣液以20~40mL/min的速度喷向旋流状态的微丸半成品,在微粒物料表面形成包衣膜层,包衣结束后,冷冻干燥,即得。
进一步地,所述步骤S1中的复合稳定剂由甘草酸、羟乙基纤维素和水按重量比12~15:0.3~1.3:100混合而成。
更进一步地,所述步骤S1中的复合稳定剂由甘草酸、羟乙基纤维素和水按重量比13:0.9:100混合而成。
进一步地,所述步骤S2中的设置包衣装置的进风温度控制在30~35℃,雾化压力为0.1~0.3MPa。
进一步地,所述步骤S2中的肠溶包衣液的制备方法如下:
将20~40份羟丙基甲基纤维素,20~50份魔芋葡甘露聚糖,8~15份成膜助剂,2~6份聚乙二醇400混合后加入300~600份pH为6的磷酸盐缓冲液中,充分搅拌溶解制成均匀的混合溶液,即得。
更进一步地,所述成膜助剂为邻苯二甲酸乙酸纤维素和聚乙烯吡咯烷酮按重量比5~11:3组成;所述聚乙烯吡咯烷酮的相对分子质量为40000。
进一步地,所述步骤2中控制最终产品中肠溶包衣层质量占产品颗粒总质量的3~15%。
本发明组合物中添加的由黄芪苷、云芝糖肽、决明子提取物按一定比例组分的天然复合提取物,科学合理配伍,协同增效,对大肠杆菌、金黄色葡萄球菌、痢疾杆菌、沙门氏菌等多种肠道致病菌具有较强的抑制作用,能显著增强机体清除细胞内自由基和脂质过氧化物的能力,能促使免疫细胞发生特异性结合,刺激体内淋巴细胞、巨噬细胞等产生免疫活性,有效提高机体免疫能力,缓解体力疲劳;同时还能够与添加的益生菌粉配合使用,能有效降低肠道粘膜渗透性,从而保护肠道粘膜屏障完整性,促进肠道益生菌的增殖,维持肠道微生态的平衡,增进肠道健康。
同时,本发明中还添加了植物螯合肽,由植物螯合肽合成酶(phytochelatinsynthase,PCS)以谷胱甘肽(glutathione,GSH)为底物催化合成的小分子多肽,能通过Cys的-SH络合重金属,对重金属的解毒,防御重金属引起的氧化胁迫和必需重金属的代谢方面具有重要作用。现有技术中,对于重金属中毒,一般习惯用二巯基现醇、依地酸钙钠、青霉胺等化学药物,但是这些化学合成螯合剂会对人体产生一定的副作用,而植物螯合肽是植物提纯剂,可以在安全,对人体没有副作用的情况下,有效缓解重金属的毒害作用,尤其是对重金属镉Cd2+有特别的吸收作用,对人体更加更安全,可以有效减轻现代环境污染造成食物链重金属危害。
同时,本申请发明人意外的发现,在本发明的组分中添加一定量的植物螯合肽,能够与本发明中添加的天然复合提取物及益生菌粉产生协同作用,不仅能够作为减缓重金属中毒的植物螯合剂,还能够有效促进益生菌对于肠道菌群的调节作用,从而提高人体免疫力。从试验例二的小鼠游泳负重实验中也可以看出,当组分中未添加植物螯合肽时,小鼠的运动耐力及负重游泳时间较实施例中有了明显的下降。
另外,由于本发明中的添加的植物螯合肽,天然复合提取物及益生菌粉不能够抵抗胃肠道恶劣的环境,所以本发明通过特定的制备工艺,制粒时添加了复合稳定剂,并且以羟丙基甲基纤维素,魔芋葡甘露聚糖和成膜助剂为肠溶包衣液的主要原料,整个加工环节不需要乙醇或其他有机溶剂,并且包衣温度维持在30~35℃即可,大大的避免了制备过程对菌体及生物活性物质的影响,得到的包衣后的组合物耐酸能力强,可避免在胃液环境中被胃酸侵蚀。
与现有技术相比,本发明提供的含有植物螯合肽的组合物具有以下优势:
(1)本发明的组合物采用益生菌粉与植物螯合肽,复合天然提取物,复合氨基酸结合,能有效调节人体肠道菌群,促进营养物质的吸收,可以补充人体自身不能生成的氨基酸等营养物质,增强人体免疫力,缓解体力疲劳,同时螯合人体通过食物链吸收的重金属,起到补充营养和排毒的作用。
(2)本发明的组合物通过的包衣工艺,操作更简单,能有效提高在胃液、胆汁和胰酶的耐受能力,制得的组合物在人体内具有较低的胃部释放损失,进而提高进入肠道的活菌数,保证尽可能多的菌体到达肠道,进入肠道的益生菌与天然活性成分协同作用,还能有效保护菌体活力,真正起到保健和治疗的功效。
具体实施方式
以下通过具体实施方式的描述对本发明作进一步说明,但这并非是对本发明的限制,本领域技术人员根据本发明的基本思想,可以做出各种修改或改进,但是只要不脱离本发明的基本思想,均在本发明的保护范围之内。
云芝糖肽、决明子提取物购自扶风斯诺特生物科技有限公司;植物螯合肽,购自上海沐晋生物科技有限公司,货号MJ211026-5。
另外,本发明所用的其他试剂均为常用试剂,均可在常规试剂生产销售公司购买。
实施例1一种含有植物螯合肽的组合物及其制备方法
所述的含有植物螯合肽的组合物,包括如下组分及其重量份数:
天然复合提取物280份,植物螯合肽10份,益生菌粉70份,复合氨基酸350份;
所述复合提取物由黄芪苷、云芝糖肽、决明子提取物按重量比7:13:6组成。
所述益生菌粉由嗜酸乳杆菌、植物乳杆菌、鼠李糖乳杆菌、罗伊氏乳杆菌、瑞士乳杆菌按重量比1:1:1:1:1组成。
所述复合氨基酸由赖氨酸、色氨酸、苯丙氨酸按重量比1:1:1组成。
所述的含有植物螯合肽的组合物的制备方法,包括如下步骤:
S1、将植物螯合肽,天然复合提取物,益生菌粉,复合氨基酸混合,然后加入其重量1倍的复合稳定剂,在搅拌转速80r/min下搅拌10min,混合均匀后投入制粒机内,调节粒度为16目,冷冻干燥,得到微丸半成品;
S2、将步骤S1所得的微丸半成品投入至旋流流化床制粒包衣机中进行包膜处理,启动包衣装置,设置包衣装置的进风温度控制在30℃,雾化压力为0.1MPa,将肠溶包衣液以20mL/min的速度喷向旋流状态的微丸半成品,在微粒物料表面形成包衣膜层,控制最终产品中肠溶包衣层质量占产品颗粒总质量的3~15%,包衣结束后,冷冻干燥,即得。
所述步骤S1中的复合稳定剂由甘草酸、羟乙基纤维素和水按重量比12:0.3:100混合而成。
所述步骤S2中的肠溶包衣液的制备方法如下:
将20份羟丙基甲基纤维素,20份魔芋葡甘露聚糖,8份成膜助剂,2份聚乙二醇400混合后加入300份pH为6的磷酸盐缓冲液中,充分搅拌溶解制成均匀的混合溶液,即得。
所述成膜助剂为邻苯二甲酸乙酸纤维素,聚乙烯吡咯烷酮按重量比5:3组成;所述聚乙烯吡咯烷酮的相对分子质量为40000。
实施例2一种含有植物螯合肽的组合物及其制备方法
所述的含有植物螯合肽的组合物,包括如下组分及其重量份数:
天然复合提取物450份,植物螯合肽20份,益生菌粉120份,复合氨基酸380份;
所述天然复合提取物由黄芪苷、云芝糖肽、决明子提取物按重量比14:12:5组成;
所述益生菌粉由植物乳杆菌、鼠李糖乳杆菌、瑞士乳杆菌、短双岐杆菌按重量比2:1:1:1组成;
所述复合氨基酸由赖氨酸、色氨酸、甲硫氨酸、苏氨酸、异亮氨酸按重量比1:1:1:1:1组成。
所述的含有植物螯合肽的组合物的制备方法,包括如下步骤:
S1、将植物螯合肽,天然复合提取物,益生菌粉,复合氨基酸混合,然后加入其重量1.3倍的复合稳定剂,在搅拌转速120r/min下搅拌20min,混合均匀后投入制粒机内,调节粒度为25目,冷冻干燥,得到微丸半成品;
S2、将步骤S1所得的微丸半成品投入至旋流流化床制粒包衣机中进行包膜处理,启动包衣装置,设置包衣装置的进风温度控制在33℃,雾化压力为0.2MPa,将肠溶包衣液以30mL/min的速度喷向旋流状态的微丸半成品,在微粒物料表面形成包衣膜层,控制最终产品中肠溶包衣层质量占产品颗粒总质量的3~15%,包衣结束后,冷冻干燥,即得。
所述步骤S1中的复合稳定剂由甘草酸、羟乙基纤维素和水按重量比13:0.9:100混合而成。
所述步骤S2中的肠溶包衣液的制备方法如下:
将30份羟丙基甲基纤维素,40份魔芋葡甘露聚糖,11份成膜助剂,4份聚乙二醇400混合后加入500份pH为6的磷酸盐缓冲液中,充分搅拌溶解制成均匀的混合溶液,即得。
所述成膜助剂为邻苯二甲酸乙酸纤维素,聚乙烯吡咯烷酮按重量比8:3组成;所述聚乙烯吡咯烷酮的相对分子质量为40000。
实施例3一种含有植物螯合肽的组合物及其制备方法
所述的含有植物螯合肽的组合物,包括如下组分及其重量份数:
天然复合提取物520份,植物螯合肽30份,益生菌粉150份,复合氨基酸400份;
所述复合提取物由黄芪苷、云芝糖肽、决明子提取物按重量比16:11:1组成。
所述益生菌粉由嗜酸乳杆菌、罗伊氏乳杆菌、瑞士乳杆菌、发酵乳杆菌、乳双歧杆菌按重量比1:1:1:1:1组成;
所述复合氨基酸由赖氨酸、甲硫氨酸、异亮氨酸、亮氨酸、缬氨酸按重量比1:1:1:1:1组成。
所述的含有植物螯合肽的组合物的制备方法,包括如下步骤:
S1、将植物螯合肽,天然复合提取物,益生菌粉,复合氨基酸混合,然后加入其重量1.5倍的复合稳定剂,在搅拌转速160r/min下搅拌30min,混合均匀后投入制粒机内,调节粒度为30目,冷冻干燥,得到微丸半成品;
S2、将步骤S1所得的微丸半成品投入至旋流流化床制粒包衣机中进行包膜处理,启动包衣装置,设置包衣装置的进风温度控制在35℃,雾化压力为0.3MPa,将肠溶包衣液以40mL/min的速度喷向旋流状态的微丸半成品,在微粒物料表面形成包衣膜层,控制最终产品中肠溶包衣层质量占产品颗粒总质量的3~15%,包衣结束后,冷冻干燥,即得。
所述步骤S1中的复合稳定剂由甘草酸、羟乙基纤维素和水按重量比15:1.3:100混合而成。
所述步骤S2中的肠溶包衣液的制备方法如下:
将40份羟丙基甲基纤维素,50份魔芋葡甘露聚糖,15份成膜助剂,6份聚乙二醇400混合后加入600份pH为6的磷酸盐缓冲液中,充分搅拌溶解制成均匀的混合溶液,即得。
所述成膜助剂为邻苯二甲酸乙酸纤维素,聚乙烯吡咯烷酮按重量比11:3组成;所述聚乙烯吡咯烷酮的相对分子质量为40000。
对比例1一种含有植物螯合肽的组合物及其制备方法
与实施例2的相比,对比例1的区别在于,所述天然复合提取物由黄芪苷、云芝糖肽按重量比14:12组成,其他组分和制备方法与实施例2相同。
对比例2一种含有植物螯合肽的组合物及其制备方法
与实施例2的相比,对比例2的区别在于,所述天然复合提取物由黄芪苷和决明子提取物按重量比13:5组成,其他组分和制备方法与实施例2相同。
对比例3一种含有植物螯合肽的组合物及其制备方法
与实施例2的相比,对比例3的区别在于,所述天然复合提取物由黄芪苷、云芝糖肽、决明子提取物按重量比1:1:1组成,其他组分和制备方法与实施例2相同。
对比例4一种含有植物螯合肽的组合物及其制备方法
与实施例2的相比,对比例4的区别在于,所述的含有植物螯合肽的组合物的制备方法中,步骤S1复合稳定剂中未添加甘草酸,其他组分和制备方法与实施例2相同。
对比例5一种含有植物螯合肽的组合物及其制备方法
与实施例2的相比,对比例5的区别在于,所述的含有植物螯合肽的组合物的制备方法中,步骤S2肠溶包衣液中成膜助剂中的聚乙烯吡咯烷酮的相对分子质量为160000,其他组分和制备方法与实施例2相同。
对比例6一种含有植物螯合肽的组合物及其制备方法
与实施例2的相比,对比例6的区别在于,所述含有植物螯合肽的组合物中未添加植物螯合肽,其他组分和制备方法与实施例2相同。
试验例一、人工胃液耐受试验
1、试验材料:实施例1~3,对比例1~6制得的含有植物螯合肽的组合物。
2、试验方法:分别取本发明制得的实施例1~3,对比例1~6的含有植物螯合肽的组合物0.2g置于10mL模拟胃液中,震荡混匀,37℃水浴孵育,每隔30min取样,置于0.06mol/L的柠檬酸钠溶液中震荡处理1h(35℃,100rpm使组合物充分溶解,进行采用平板计数法,进行活菌计数。
3、试验结果
试验结果如表1所示。
表1本发明的组合物的益生菌在模拟胃液中存活率(%)
由表1可知,本发明实施例1~3制得的含有植物螯合肽的组合物,表现出良好的肠胃环境耐受能力,在模拟胃液中2小时后,益生菌的存活率仍然可以达到85%以上,其中实施例2的效果最好,为本发明的最佳实施例。而对比例4~5中当改变了制备工艺时,得到的组合物中的益生菌在模拟胃液中的存活率都有了不同程度的下降。
试验例二、小鼠游泳负重实验
1、试验材料:实施例1~3,对比例1~6制得的含有植物螯合肽的组合物。
2、试验方法:
选用清洁级ICR健康雄性小鼠100只,体重18-22g。购入的动物应先检疫3天无异常后,将小鼠分为10组,分别为空白对照组,实施例1~3组,对比例1~6组,空白对照组每日灌胃0.2ml生理盐水,实施例1~3组,对比例1~6组分别灌胃0.2ml植物螯合肽的组合物(浓度4g/kg·d),连续30天。整个实验过程动物必须喂饲质量合格的全价饲料,自由进食饮水。
30天后,将每只小鼠称重,在小鼠尾部上端绑上5%体重的铅皮,放入水深30cm、水温25℃的游泳箱内,立即计时,观察并保持每只小鼠四肢划水运动状态,记录小鼠自游泳开始至死亡的时间,作为小鼠负重游泳时间。
3、试验结果
试验结果如表2所示。
表2小鼠体重及负重游泳时间
组别 | 初体重(g) | 末体重(g) | 游泳时间(min) |
空白对照组 | 18.8±0.2 | 32.3±2.5 | 13.3±2.4 |
实施例1组 | 19.2±1.0 | 44.4±2.5 | 19.9±2.8 |
实施例2组 | 18.4±1.0 | 45.6±2.6 | 22.4±4.1 |
实施例3组 | 19.2±0.7 | 44.3±3.0 | 20.9±4.4 |
对比例1组 | 18.8±0.8 | 36.6±3.1 | 15.8±3.1 |
对比例2组 | 18.8±0.3 | 35.6±2.8 | 15.6±3.2 |
对比例3组 | 18.5±0.9 | 38.8±3.1 | 16.2±2.3 |
对比例4组 | 18.9±0.8 | 35.7±2.7 | 15.4±3.6 |
对比例5组 | 19.3±0.4 | 34.1±2.9 | 14.0±3.4 |
对比例6组 | 18.3±0.5 | 40.1±2.3 | 14.7±3.0 |
由表2可知,对小鼠连续灌胃30天本发明实施例1~3制得的含有植物螯合肽的组合物后,显著的延长了小鼠的负重游泳时间,增强了小鼠的运动耐力,实施例2组的小鼠30天后的体重达到了45.6±2.6g,负重游泳时间为21.2±4.1min,而对比例1~6的小鼠在30天的饲养中体重增长较慢,并且负重游泳的时间较实施例1~3组中有了明显的下降。
上述实施例仅例示性说明本发明的原理及其功效,而非用于限制本发明。任何熟悉此技术的人士皆可在不违背本发明的精神及范畴下,对上述实施例进行修饰或改变。因此,举凡所属技术领域中具有通常知识者在未脱离本发明所揭示的精神与技术思想下所完成的一切等效修饰或改变,仍应由本发明的权利要求所涵盖。
Claims (6)
1.一种含有植物螯合肽的组合物,其特征在于,包括如下组分及其重量份数:天然复合提取物280~520份,植物螯合肽10~30份,益生菌粉70~150份,复合氨基酸350~400份;
所述复合提取物由黄芪苷、云芝糖肽、决明子提取物按重量比7~16:11~13:1~6组成;
所述的含有植物螯合肽的组合物的制备方法,包括如下步骤:
S1、将植物螯合肽,天然复合提取物,益生菌粉,复合氨基酸混合,然后加入其重量1~1.5倍的复合稳定剂,在搅拌转速80~160r/min下搅拌10~30min,混合均匀后投入制粒机内,调节粒度为16~30目,冷冻干燥,得到微丸半成品;
S2、将步骤S1所得的微丸半成品投入至旋流流化床制粒包衣机中进行包膜处理,启动包衣装置,将肠溶包衣液以20~40mL/min的速度喷向旋流状态的微丸半成品,在微粒物料表面形成包衣膜层,包衣结束后,冷冻干燥,即得;
所述步骤S1中的复合稳定剂由甘草酸、羟乙基纤维素和水按重量比12~15:0.3~1.3:100混合而成;
所述步骤S2中的肠溶包衣液的制备方法如下:
将20~40份羟丙基甲基纤维素,20~50份魔芋葡甘露聚糖,8~15份成膜助剂,2~6份聚乙二醇400混合后加入300~600份pH为6的磷酸盐缓冲液中,充分搅拌溶解制成均匀的混合溶液,即得;
所述成膜助剂为邻苯二甲酸乙酸纤维素和聚乙烯吡咯烷酮按重量比5~11:3组成,所述聚乙烯吡咯烷酮的相对分子质量为40000。
2.如权利要求1所述的含有植物螯合肽的组合物,其特征在于,包括如下组分及其重量份数:天然复合提取物450份,植物螯合肽20份,益生菌粉120份,复合氨基酸380份;
所述复合提取物由黄芪苷、云芝糖肽、决明子提取物按重量比14:12:5组成;
所述益生菌粉含有嗜酸乳杆菌、植物乳杆菌、鼠李糖乳杆菌、罗伊氏乳杆菌、瑞士乳杆菌、发酵乳杆菌、动物双歧杆菌、乳双歧杆菌或短双岐杆菌中的两种或两种以上的混合菌种;
所述复合氨基酸为赖氨酸、色氨酸、苯丙氨酸、甲硫氨酸、苏氨酸、异亮氨酸、亮氨酸、缬氨酸中的两种或两种以上。
3.如权利要求1或2所述的含有植物螯合肽的组合物,其特征在于,所述含有植物螯合肽的组合物还包括营养学上可接受的赋形剂、载体或稀释剂。
4.如权利要求1所述的含有植物螯合肽的组合物,其特征在于,所述步骤S1中的复合稳定剂由甘草酸、羟乙基纤维素和水按重量比13:0.9:100混合而成。
5.如权利要求1所述的含有植物螯合肽的组合物,其特征在于,所述步骤S2中的设置包衣装置的进风温度控制在30~35℃,雾化压力为0.1~0.3MPa。
6.如权利要求1所述的含有植物螯合肽的组合物,其特征在于,所述步骤S2中控制最终产品中肠溶包衣层质量占产品颗粒总质量的3~15%。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111314565.3A CN113995142B (zh) | 2021-11-08 | 2021-11-08 | 一种含有植物螯合肽的组合物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111314565.3A CN113995142B (zh) | 2021-11-08 | 2021-11-08 | 一种含有植物螯合肽的组合物及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113995142A CN113995142A (zh) | 2022-02-01 |
CN113995142B true CN113995142B (zh) | 2022-04-26 |
Family
ID=79928072
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111314565.3A Active CN113995142B (zh) | 2021-11-08 | 2021-11-08 | 一种含有植物螯合肽的组合物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113995142B (zh) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002012446A1 (fr) * | 2000-04-26 | 2002-02-14 | Bingxin Wu | Culture et fermentation de bacteries intestinales benefiques pour la transformation et la modification de medicaments naturels |
CN102551139A (zh) * | 2011-12-29 | 2012-07-11 | 山西汉波食品股份有限公司 | 红枣黄芪减肥浓浆 |
CN104522750A (zh) * | 2014-12-18 | 2015-04-22 | 威海百合生物技术股份有限公司 | 一种藻类保健食品 |
CN105061093A (zh) * | 2015-09-09 | 2015-11-18 | 山东乡约生物工程科技有限公司 | 一种植物螯合肽微生物菌剂及其制备方法 |
CN106726664A (zh) * | 2016-12-28 | 2017-05-31 | 安徽檀鑫科技有限公司 | 一种深层美白祛斑精华霜及其制备方法 |
WO2020137706A1 (ja) * | 2018-12-28 | 2020-07-02 | 小林製薬株式会社 | シクロアストラゲノール類縁体を生産する方法 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7604823B2 (en) * | 2006-09-07 | 2009-10-20 | Jose Angel Olalde Rangel | Synergistic HIV/AIDS and/or immune disease phyto-nutraceutical composition |
-
2021
- 2021-11-08 CN CN202111314565.3A patent/CN113995142B/zh active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002012446A1 (fr) * | 2000-04-26 | 2002-02-14 | Bingxin Wu | Culture et fermentation de bacteries intestinales benefiques pour la transformation et la modification de medicaments naturels |
CN102551139A (zh) * | 2011-12-29 | 2012-07-11 | 山西汉波食品股份有限公司 | 红枣黄芪减肥浓浆 |
CN104522750A (zh) * | 2014-12-18 | 2015-04-22 | 威海百合生物技术股份有限公司 | 一种藻类保健食品 |
CN105061093A (zh) * | 2015-09-09 | 2015-11-18 | 山东乡约生物工程科技有限公司 | 一种植物螯合肽微生物菌剂及其制备方法 |
CN106726664A (zh) * | 2016-12-28 | 2017-05-31 | 安徽檀鑫科技有限公司 | 一种深层美白祛斑精华霜及其制备方法 |
WO2020137706A1 (ja) * | 2018-12-28 | 2020-07-02 | 小林製薬株式会社 | シクロアストラゲノール類縁体を生産する方法 |
Non-Patent Citations (3)
Title |
---|
Distribution of phytochelatins, metal-binding compounds, in plant foods: A survey of commonly consumed fruits,vegetables,grains and legumes;Kristine K.Dennis et al.;《Food Chemistry》;20200910;第1-9页 * |
Phytochelatin database:a resource for phytochelatin complexes of nutritional and environmental metals;Kristine K.Dennis et al.;《DATABASE》;20191231;文章ID baz083 第1-9页 * |
益生菌与药食同源植物的协同作用;李曼莎等;《食品工业》;20180920(第09期);第232-236页 * |
Also Published As
Publication number | Publication date |
---|---|
CN113995142A (zh) | 2022-02-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR102188020B1 (ko) | 락토바실러스 파라카제이 균주 및 그 용도 | |
KR101493302B1 (ko) | 선택된 비병원성 미생물에 의한 천연 폴리사카라이드의 프로세싱 및 이의 제조 방법 및 사용 방법 | |
CN105454966A (zh) | 改善胃肠道且提高免疫力的益生菌固体饮料及其制备方法 | |
CN115074274B (zh) | 含乳酸菌的组合物及其用途 | |
JP2014047212A (ja) | ラクトバチラス‐プランタルムcmu995菌株の使用方法 | |
CA3093380A1 (en) | Compositions for use in balancing microbiome | |
CN111011867B (zh) | 一种益生菌包埋颗粒及其制备方法 | |
CA2281463A1 (en) | Composition comprising micronutrients in combination with prebiotics, probiotics, and synbiotics | |
JP2000095697A (ja) | 抗アレルギー剤 | |
WO2022000080A1 (en) | Compositions and related methods for supporting companion animals with gastrointestinal disorders | |
EP3307290A1 (en) | Dietary supplement | |
Cao et al. | Effects of diosmectite-Lactobacillus acidophilus on growth performance, intestine microbiota, mucosal architecture of weaned pigs | |
KR101378974B1 (ko) | 고농축 락토바실러스균을 함유하는 장용성 캡슐 제제 및 그의 제조방법 | |
SG190781A1 (en) | Method for inhibiting pathogens using a nutritional composition | |
MX2013005943A (es) | Uso de composiciones nutricionales que incluyen lactoferrina en apoyo de la resistencia a enfermedades y condiciones. | |
CN108669563A (zh) | 一种组合物、其应用和增强免疫力、改善过敏的产品 | |
CN113995142B (zh) | 一种含有植物螯合肽的组合物及其制备方法 | |
CN113939281A (zh) | 微生物组合物和用于增加耐受性并延长保质期的方法 | |
CN114933984B (zh) | 一种促进体内塑化剂及重金属排出的益生菌益生元复合组合物及其制备方法 | |
CN115337327A (zh) | 一种具有降脂、抗炎和抗氧化功能的益生菌制剂的制备方法和应用 | |
KR101191893B1 (ko) | 초유로부터 분리한 공액리놀레산 생산 균주 및 그 용도 | |
TWM610134U (zh) | 可包覆益生菌於腸胃道緩慢釋放之載體結構 | |
CN117384790B (zh) | 一株戊糖片球菌ks5及其在制备助睡眠药品中的应用 | |
CN114304688B (zh) | 玉米醇溶蛋白包被剂、利用该包被剂进行包被的益生菌制剂及其制备方法 | |
CN115997933B (zh) | 一种蛋黄球蛋白益生菌粉及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB02 | Change of applicant information | ||
CB02 | Change of applicant information |
Address after: 5 / F, 3 gale street, London, UK Applicant after: Neugeffen biotechnology International Group Holdings Ltd. Applicant after: Zhou Yanzhong Address before: 5th floor, 3 Goyle street, Greater London Applicant before: Neugeffen biotechnology International Group Holdings Ltd. Applicant before: Zhou Yanzhong |
|
GR01 | Patent grant | ||
GR01 | Patent grant |